IMUX NASDAQ
Credit Risk of going bust: lower than 65% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Immunic, Inc. would be worth roughly what it owes.
Total debt $567K against a stock market value of $99.3M.
Distance to default 6.82 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $284K (short-term plus half of long-term), stock volatility 81.9%; Altman Z'' -9.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10036
US
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | A-Award | 25,370 | $10.12 | 2026-09-16 |
| Nagel Robert Thorval | A-Award | 25,370 | $10.12 | 2026-09-16 |
| Ridloff Elena | 0 | — | 2026-08-06 | |
| Ridloff Elena | A-Award | 50,740 | $14.54 | 2026-08-06 |
| Skerjanec Simona | A-Award | 25,370 | $14.80 | 2026-07-05 |